18 research outputs found
Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts
The pleiotropic cytokine IL-6 accelerates the progression of breast cancer in a variety of preclinical models through the activation of the STAT3 (signal transducer and activator of transcription 3) signaling pathway. However, the proportion of breast cancers sensitive to anti-IL-6 therapies is not known. This study evaluates the efficacy of anti-IL-6 therapies using breast cancer patient derived xenografts (PDXs). During the generation of our collection of PDXs, we showed that the successful engraftment of tumor tissue in immunodeficient mice correlates with bad prognosis. Four PDXs out of six were resistant to anti-IL-6 therapies and the expression of IL-6, its receptor or the levels of phospho-STAT3 (the active form of the signal transducer) did not correlate with sensitivity. Using cell cultures established from the PDXs as well as samples from in vivo treatments, we showed that only tumors in which the activation of STAT3 depends on IL-6 respond to the blocking antibodies. Our results indicate that only a fraction of breast tumors are responsive to anti-IL-6 therapies. In order to identify responsive tumors, a functional assay to determine the dependence of STAT3 activation on IL-6 should be performed
Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma
MYC; Omomyc; MelanomaMYC; Omomyc; MelanomaMYC; Omomyc; MelanomaMYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway—the most predominantly mutated pathway in this disease—turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease.M.F.Z.-F. was supported by the Juan de la Cierva Programme of the Spanish Ministry of Economy and Competitiveness (IJCI-2014-22403) and Fundació La Marató de TV3 (grant 474/C/2019); F.G. was supported by Spanish Ministry of Science and Innovation Contratos Predoctorales de Formación en Investigación en Salud (PFIS; FI20/00274); I.G.-L. was supported by a grant from the University Teacher Training Program (FPU), Ministry of Universities (FPU20/04812); and S.M.-M. was supported by the Generalitat de Catalunya “Contractació de Personal Investigador Novell (FI-DGR)” 2016 fellowship (2016FI_B 00592). This project was funded by grants from the Spanish Ministry of Science and Innovation (Fondo de Inversión en Salud [FIS] PI19/01277, which also supported I.G.-L. and S.M.-M, and Retos-Colaboración 2019 RTC2019-007067-1), La Marató TV3, the Generalitat de Catalunya AGAUR 2017 grant SGR-3193, and the European Research Council (ERC-PoC II/3079/SYST-iMYC [813132]). We thank the rest of the Soucek laboratory for critical reading of the manuscript, and the personnel at Vall d'Hebron Research Institute (VHIR) High Technology Unit. We acknowledge Vall d'Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment
Recommended from our members
The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets
Zacarías-Fluck, et al identify and validate the Wnt receptor Fzd9 as a key effector of Myc-Wnt signaling cross-talk in a mouse model of Myc-driven pancreatic insulinomas. The huge cadre of genes regulated by Myc has obstructed the identification of critical effectors that are essential for Myc-driven tumorigenesis. Here, we describe how only the lack of the receptor Fzd9, previously identified as a Myc transcriptional target, impairs sustained tumor expansion and β-cell dedifferentiation in a mouse model of Myc-driven insulinoma, allows pancreatic islets to maintain their physiological structure and affects Myc-related global gene expression. Importantly, Wnt signaling inhibition in Fzd9-competent mice largely recapitulates the suppression of proliferation caused by Fzd9 deficiency upon Myc activation. Together, our results indicate that the Wnt signaling receptor Fzd9 is essential for Myc-induced tumorigenesis in pancreatic islets
The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets.
From immune surveillance to tumor-immune escape: the story of an enemy with multiple strategies of resistance and counterattack
Tumors must circumvent the immune response of the host to
become clinically detectable. For this purpose, malignant cells
have devised multiple strategies to thwart immune attack. These
mechanisms are suggested to conspire in advanced stages of cancer to limit the ability of the immune system to restrain the tumor
and the effectiveness of immunotherapy strategies to successfully
eradicate malignant cells. From tumor biology to cancer immunotherapy and back again, we will summarize here some of the
most important mechanisms used by tumors to evade the immune response and their potential impact in the design of cancer
immunotherapy strategies.Los tumores deben evadir la respuesta inmunológica para ser
clínicamente detectables en el paciente. A estos fines, las células
cancerosas han desarrollado múltiples estrategias para eludir el
ataque inmunológico. Estos mecanismos conspiran en estadíos
avanzados de un tumor limitando la habilidad del sistema inmune para inhibir el crecimiento tumoral y la efectividad de estrategias de inmunoterapia en cáncer. Desde la biología tumoral a
la clínica, en el presente artículo expondremos los más importantes mecanismos utilizados por tumores para evadir la respuesta
inmunológica y su potencial impacto en el diseño de estrategias
de inmunoterapia
Regulatory T cells but not NKT I cells are modulated by a single low-dose cyclophosphamide in a B cell lymphoma tumor-model
Aim: Experimental and clinical studies showed that the administration of cyclophosphamide (Cy) in low doses leads to an enhancement of the antitumor immune response. Our objective was to study the modulation, if any, by low dose Cy, of T regulatory (Treg) and natural killer T (NKT) I cells, two cell populations of the innate immune response with opposing effects on the tumors, in a rat B cell lymphoma model. Methods: Inbred e rats were challenged s.c. with L-TACB lymphoma and on day 14 animals were distributed in two groups. Treated: injected i.p. with cyclophosphamide (10mg/kg of body weight) and Control: injected i.p. with saline. Blood samples were taken from days 0 to 21 and the percentage of T regulatory and natural killer T I cells were determined by flow cytometry. Results: We found that the increase of natural and inducible T regulatory cells of peripheral blood achieved during tumor growth was significantly downregulated by cyclophosphamide. On the contrary, natural killer T I cells were not modulated by the treatment. Conclusion: The antimetastatic effect of a single low dose of Cy would be due, at least in part, to downregulation of natural and inducible T regulatory cells
Inmunomodulación y antiangiogénesis en la terapéutica oncológica. De la investigación básica a la clínica
La investigación básica y pre-clínica en oncología celular y molecular son pilares fundamentales en los que se apoyan la mayoría de los adelantos en la terapéutica del cáncer. Los hallazgos obtenidos y su aplicación en la práctica clínica constituyen la causa del avance sostenido en el tratamiento de la enfermedad neoplásica. El objetivo de este trabajo es resumir y discutir los resultados pre-clínicos en inmunomodulación y anti-angiogénesis para el tratamiento de diversos tipos de tumores, obtenidos en nuestro Instituto durante los últimos 15 años, y la posterior traslación y aplicación del conocimiento experimental en un Ensayo Clínico Fase I/II. Se describen los resultados que contribuyeron a descifrar los mecanismos de acción de la inmunomodulación antimetastásica con ciclofosfamida, la quimioterapia metronómica con diferentes drogas únicas o combinaciones, y finalmente el diseño y resultados preliminares de un ensayo clínico de quimioterapia metronómica para pacientes con cáncer de mama avanzado.Immunomodulation and antiangiogenesis in cancer therapy. From basic to clinical research. Basic and pre-clinic research in cellular and molecular oncology are the main supports accounting for the advancement in cancer therapeutics. The findings achieved, and their implementation in clinical practice are responsible for the permanent improvement in the treatment of the neoplastic disease. Our present objective is to summarize and discuss the pre-clinical findings in immunomodulation and anti-angiogenesis for the treatment of several types of tumors obtained in our Institute during the last 15 years, and the subsequent translation and application of the acquired experimental knowledge in a Phase I/II Clinical Trial. We present the results and mechanisms of action of antimetastatic immunomodulation with cyclophosphamide, the metronomic chemotherapy with different single drugs and their combinations, and finally the design and preliminary results of a clinical trial with metronomic chemotherapy for patients with advanced breast cancer
A mammary adenocarcinoma murine model suitable for the study of cancer immunoediting
La inmunoedición del cáncer es un proceso dinámico compuesto de tres fases: eliminación (EL), equilibrio (EQ) y escape (ES) que abarca las posibles funciones protectoras del huésped y de esculpir el tumor del sistema inmunitario durante el desarrollo del tumor. Los modelos animales son herramientas útiles para estudiar enfermedades como el cáncer. El presente estudio fue diseñado para caracterizar la interacción entre el adenocarcinoma mamario M-406 y CBi, CBi - y CBi / L líneas de ratones endogámicCancer immunoediting is a dynamic process composed of three phases: elimination (EL), equilibrium (EQ) and escape (ES) that encompasses the potential host-protective and tumor-sculpting functions of the immune system throughout tumor development. Animal models are useful tools for studying diseases such as cancer. The present study was designed to characterize the interaction between mammary adenocarcinoma M-406 and CBi, CBi− and CBi/L inbred mice lines.Fil: Pagura, Lucas. Facultad de Ciencias Bioquímicas y Farmacéuticas. Universidad Nacional de Rosario; Rosario; ArgentinaFil: Cáceres, Juan Manuel. Facultad de Ciencias Médicas. Universidad Nacional de Rosario; Rosario; ArgentinaFil: Cardinali, Albertina. Facultad de Ciencias Médicas. Universidad Nacional de Rosario; Rosario; ArgentinaFil: Scharovsky, Graciela Olga. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; ArgentinaFil: Di Masso, Ricardo José. Facultad de Ciencias Médicas. Universidad Nacional de Rosario; Rosario; ArgentinaFil: Zacarias-Fluck, Mariano. Preclinical Research. Vall d’Hebron Institute of Oncology (VHIO); Barcelona; SpainFil: Rico, María José. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; ArgentinaFil: Rozados, Viviana R. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentin
The Immune Response and the Therapeutic Effect of Metronomic Chemotherapy With Cyclophosphamide
Metronomic chemotherapy (MCT) is a novel therapeutic strategy for cancer treatment endowed with an
antiangiogenic effect. It refers to regular administration of low doses of cytotoxic drugs, with minimal or
no drug-free breaks. Previously, we demonstrated the immunomodulating activity of a single low-dose of
cyclophosphamide (Cy) and the antitumor effect of MCT with Cy on established rat lymphomas and sarcomas.
Here, we examined whether the immune response is responsible for the antitumor effect of MCT with
Cy on L-TACB lymphoma. Inbred e rats and nude mice were subcutaneously challenged with L-TACB.
After 7 days, they were distributed into two experimental groups: 1) treated animals, which were injected
IP with Cy (10 mg/kg body weight) three times per week, and 2) control animals, which received IP saline
injections. Exponential growth and decay and tumor doubling time were calculated. Also, serum IL-10 levels
were measured. One hundred percent of treated rats showed tumor regression versus 0% of control rats. The
increase of tumor-induced IL-10 levels was reverted by the treatment with Cy. On the other hand, there
were no tumor regressions, in treated or control nude mice. However, the tumor doubling times of treated
nude mice were significantly higher than those of control mice, implying that other antitumor mechanism(s),
independent of the adaptive immune response, might be taking place. Our present results indicate that modulation
of the immune response would be involved in the antitumor effect of MCT with Cy, because the
absence of the specific immune response impairs, at least in part, its therapeutic effect in a lymphoma tumor
model